
    
      The primary analysis will occur after all participants have either discontinued the study or
      completed at least 6 months of treatment. After the primary analysis, the main study will be
      closed. Participants who are still on study at least 6 months after enrollment of the last
      participant in the study may be eligible to continue receiving study drug in a separate
      extension phase of the protocol
    
  